GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Forward PE Ratio

AbbVie (WBO:ABBV) Forward PE Ratio : 14.35 (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is AbbVie Forward PE Ratio?

AbbVie's Forward PE Ratio for today is 14.35.

AbbVie's PE Ratio without NRI for today is 18.01.

AbbVie's PE Ratio for today is 58.47.


AbbVie Forward PE Ratio Historical Data

The historical data trend for AbbVie's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Forward PE Ratio Chart

AbbVie Annual Data
Trend 2018-12 2019-12 2020-12 2021-12 2022-12 2023-12 2024-04
Forward PE Ratio
9.90 9.01 8.50 9.28 14.06 13.85 14.45

AbbVie Quarterly Data
2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 11.93 10.71 9.90 9.24 8.18 7.85 9.01 7.35 9.85 7.11 8.50 8.47 9.07 7.71 9.28 11.44 10.86 11.56 14.06 14.35 12.25 13.66 13.85 16.08

Competitive Comparison of AbbVie's Forward PE Ratio

For the Drug Manufacturers - General subindustry, AbbVie's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Forward PE Ratio falls into.



AbbVie Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


AbbVie  (WBO:ABBV) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


AbbVie Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of AbbVie's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (WBO:ABBV) Business Description

Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

AbbVie (WBO:ABBV) Headlines

From GuruFocus

Abbvie Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc To Acquire Cerevel Therapeutics Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024